Hematopoietic stem cell transplantation: A global perspective

JAMA

Volumn 303, Issue 16, 2010, Pages 1617-1624

  Gratwohl, Alois ^a   Baldomero, Helen ^a   Aljurf, Mahmoud ^b   Pasquini, Marcelo C ^c   Bouzas, Luis Fernando ^d   Yoshimi, Ayami ^e   Szer, Jeff ^f   Lipton, Jeff ^g   Schwendener, Alvin ^h   Gratwohl, Michael ^h   Frauendorfer, Karl ^h   Niederwieser, Dietger ⁱ   Horowitz, Mary ^c   Kodera, Yoshihisa ^j  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h UNIVERSITY OF ST GALLEN   (Switzerland)

ⁱ UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^j AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DONOR; ECONOMIC ASPECT; EUROPE; GEOGRAPHIC DISTRIBUTION; GOVERNMENT; HEALTH CARE COST; HUMAN; INCOME; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT INDICATION; UNITED STATES; WORLD HEALTH ORGANIZATION; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; DEVELOPING COUNTRY; ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFORMATION PROCESSING; STATISTICS; UTILIZATION REVIEW;

DATA COLLECTION; DEVELOPING COUNTRIES; ECONOMICS; HEALTH EXPENDITURES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCOME; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77951623928     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.491     Document Type: Article

References (30)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-1826.
2. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357(15):1472-1475.
3. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al; European Group for Blood and Marrow. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 2006;37(5):439-449.
4. Daikeler T, Hügle T, Farge D, et al; Working Party Autoimmune Diseases of the EBMT. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant. 2009;44(1):27-33.
5. Hirano M, Martí R, Casali C, et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology. 2006;67(8):1458-1460. (Pubitemid 44632073)
6. Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112(9):1992-2001. (Pubitemid 351574075)
7. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum: report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009; 15(3):367-369.
8. Appelbaum FR. What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)? Best Pract Res Clin Haematol. 2008;21(4):667-675.
9. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by lowdose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;24(3):444-453. (Pubitemid 46630463)
10. Horowitz MM. Uses and growth of hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin E, Blume KG, eds. Hematopoietic Cell Transplantation. 3rd ed. Hoboken, NJ: Blackwell Publishing; 2009:9-15.
11. Tan SS, Uyl de-Groot CA, Huijgens PC, Fibbe WE. Stem cell transplantation in Europe: trends and prospects. Eur J Cancer. 2007;43(16):2359-2365.
12. Saito AM, Cutler C, Zahrieh D, et al. Costs of allogeneic hematopoietic cell transplantation with highdose regimens. Biol Blood Marrow Transplant. 2008;14(2):197-207.
13. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658-3666.
14. Gajewski JL, Robinson P. Do affluent societies have the only options for the best therapy? Leukemia. 2007;21(3):387-388. (Pubitemid 46306548)
15. Swanson RC, Mosley H, Sanders D, et al. Call for global health-systems impact assessments. Lancet. 2009;374(9688):433-435.
16. Gratwohl A; European Group for Bone Marrow Transplantation (EBMT). Bone marrow transplantation activity in Europe 1990: report from the European Group for Bone Marrow Transplantation (EBMT). Bone Marrow Transplant. 1991;8(3):197-201.
17. Kodera Y. The Japan Marrow Donor Program, the Japan Cord Blood Bank Network and the Asia Blood and Marrow Transplant Registry. Bone Marrow Transplant. 2008;42(suppl 1):S6.
18. Nivison-Smith I, Bradstock KF, Dodds AJ, et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant. 2007;13(8):905-912.
19. Horowitz M. The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008;42(suppl 1):S1-S2.
20. Aljurf MD, Zaidi SZ, El Solh H, et al. Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report. Bone Marrow Transplant. 2009;43(1):1-12.
21. Gratwohl A, Passweg J, Baldomero H, Horisberger B, Urbano-Ispizua A; Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Economics, health care systems and utilisation of haematopoietic stem cell transplants in Europe. Br J Haematol. 2002;117(2):451-468.
22. Gratwohl A, Baldomero H, Schwendener A, et al; Joint Accreditation Committee of the International Society for Cellular Therapy; European Group for Blood and Marrow Transplantation; European Leukemia Net. Predictability of hematopoietic stem cell transplantation rates. Haematologica. 2007;92(12):1679-1686.
23. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Urbano-Ispizua A, Frauendorfer K. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe: impact of cost considerations. Leukemia. 2007;21(3):383-386. (Pubitemid 46306547)
24. Gratwohl A, Stern M, Brand R, et al; European Group for Blood and Marrow Transplantation and the European Leukemia Net. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115(20):4715-4726.
25. Aubrey P, Arber S, Tyler M. The organ donor crisis: the missed organ donor potential from the accident and emergency departments. Transplant Proc. 2008;40(4):1008-1011. (Pubitemid 351794312)
26. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol. 2007;211(1):27-35. (Pubitemid 46363893)
27. Novotny NM, Ray R, Markel TA, et al. Stem cell therapy in myocardial repair and remodeling. J Am Coll Surg. 2008;207(3):423-434.
28. Beeres SL, Atsma DE, van Ramshorst J, Schalij MJ, Bax JJ. Cell therapy for ischaemic heart disease. Heart. 2008;94(9):1214-1226.
29. Einstein O, Ben-Hur T. The changing face of neural stem cell therapy in neurologic diseases. Arch Neurol. 2008;65(4):452-456. (Pubitemid 351549952)
30. Barclay E. Stem-cell experts raise concerns about medical tourism. Lancet. 2009;373(9667):883-884.